Asim Razzaq, MD
Rheumatology · Murfreesboro, TNNPI 1790758514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 614 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,281 and has fallen 52.4% since, to $1,085 in 2025.
Across 614 payments — averaging $13.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Novartis$912
- E.r. Squibb & Sons, L.L.C.$563
- Johnson & Johnson$549
- Lilly USA, LLC$523
- plus $2K from 23 others
What the payments were for
- Food & beverage$8,38098%
- Education$1912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 179 | $1,914 |
| Amgen(2 entities) | 105 | $1,623 |
| Novartis | 64 | $912 |
| E.r. Squibb & Sons, L.L.C. | 38 | $563 |
| Johnson & Johnson | 33 | $549 |
| Lilly USA, LLC | 37 | $523 |
| Pfizer | 25 | $425 |
| GSK | 23 | $394 |
| UCB, Inc. | 29 | $377 |
| Genentech USA, Inc. | 20 | $231 |
| Sanofi | 7 | $154 |
| Regeneron Healthcare Solutions, Inc. | 10 | $145 |
| AstraZeneca | 8 | $142 |
| Hikma Pharmaceuticals USA | 7 | $127 |
| Mallinckrodt Hospital Products Inc. | 4 | $89 |
| Bristol Myers Squibb | 4 | $81 |
| Radius Health, Inc. | 5 | $66 |
| Sobi, Inc | 2 | $43 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Medexus Pharma, Inc. | 2 | $26 |
| Merck | 2 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$8,571 in reported general payments places this provider in the 55th percentile of 127 rheumatology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel MiniEtanercept | 109 | $833,819 |
| RinvoqUpadacitinib | 89 | $567,289 |
| Humira(Cf) PenAdalimumab | 65 | $457,884 |
| Enbrel SureclickEtanercept | 50 | $368,612 |
| Orencia ClickjectAbatacept | 29 | $161,678 |
| Humira(Cf)Adalimumab | 18 | $123,611 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $88,362 |
| Xeljanz XrTofacitinib Citrate | 14 | $76,468 |
| SaphneloAnifrolumab-Fnia | 13 | $63,044 |
| ProliaDenosumab | 22 | $38,380 |
| Hydroxychloroquine Sulfate | 797 | $21,671 |
| MethotrexateMethotrexate Sodium | 618 | $13,344 |
| Mycophenolic AcidMycophenolate Sodium | 14 | $12,121 |
| Leflunomide | 146 | $10,956 |
| Febuxostat | 43 | $4,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,914 | $690,899107 claims |
| UCB, Inc.Cimzia (2 Pack) | $377 | $88,36215 claims |
| AstraZenecaSaphnelo | $142 | $63,04413 claims |
| AmgenProlia | $1,623 | $38,38022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 127 rheumatology providers in Tennessee.
Other rheumatology in Murfreesboro
- Marcus OwenMurfreesboro$324K
- Joseph HuffstutterHixson$742K
- Brett SmithKnoxville$587K
- Satish OdhavJackson$527K
- Jacob AelionJackson$459K
- Mohammad AliHendersonville$251K
- Victor ByrdNashville$247K
- Ramesh GuptaMemphis$81K
- Christian RheaNashville$81K
- Tyler ReeseNashville$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.